Ralfinamide - Newron Pharmaceuticals
Alternative Names: NW-1029; PriralfinamideLatest Information Update: 07 Jan 2020
At a glance
- Originator Newron Pharmaceuticals; Purdue Biopharma
- Developer Newron Pharmaceuticals
- Class Amides; Analgesics; Fluorobenzenes; Small molecules
- Mechanism of Action N-type calcium channel antagonists; Nav1.7 voltage-gated sodium channel inhibitors; NMDA receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain; Psychiatric disorders
Highest Development Phases
- Phase III Neuropathic pain
- Discontinued Dental pain; Inflammatory pain
Most Recent Events
- 07 Jan 2020 Ralfinamide is still in phase III for Neuropathic pain in the United Kingdom, Germany, Italy, Poland, Romania and India
- 09 Sep 2015 Phase-II/III development is still ongoing for Neuropathic pain in the EU and India
- 21 Aug 2012 Discontinued - Phase-II for Dental pain in India (PO)